Equasens Société anonyme (0R9T.L)
EUR 44.15
(1.03%)
EUR 44.15
(1.03%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 55.2 Million EUR | 0.35% |
| 2022 | 55.21 Million EUR | 9.84% |
| 2021 | 50.26 Million EUR | 8.95% |
| 2020 | 46.13 Million EUR | 12.94% |
| 2019 | 40.84 Million EUR | 4.78% |
| 2018 | 38.98 Million EUR | 13.79% |
| 2017 | 34.26 Million EUR | 9.16% |
| 2016 | 31.38 Million EUR | 11.24% |
| 2015 | 28.21 Million EUR | 10.71% |
| 2014 | 25.48 Million EUR | 10.22% |
| 2013 | 23.12 Million EUR | 14.79% |
| 2012 | 20.14 Million EUR | 11.99% |
| 2011 | 17.98 Million EUR | 3.98% |
| 2010 | 17.29 Million EUR | 14.99% |
| 2009 | 15.04 Million EUR | 482.04% |
| 2008 | -3.93 Million EUR | 65.21% |
| 2007 | -11.31 Million EUR | -198.41% |
| 2006 | 11.5 Million EUR | 19.56% |
| 2005 | 9.61 Million EUR | 13.62% |
| 2004 | 8.46 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 10.11 Million EUR | -27.49% |
| 2024 Q2 | 10.11 Million EUR | 0.0% |
| 2023 FY | 55.4 Million EUR | 0.35% |
| 2023 Q2 | 27.25 Million EUR | 98.69% |
| 2023 Q3 | 13.95 Million EUR | -48.81% |
| 2023 Q4 | 13.95 Million EUR | 0.0% |
| 2023 Q1 | 13.71 Million EUR | -55.2% |
| 2022 Q4 | 30.61 Million EUR | 0.0% |
| 2022 Q1 | 12.8 Million EUR | -50.4% |
| 2022 FY | 55.21 Million EUR | 9.84% |
| 2022 Q2 | 25.61 Million EUR | 100.0% |
| 2021 Q2 | 24.44 Million EUR | 100.0% |
| 2021 FY | 50.26 Million EUR | 8.95% |
| 2021 Q3 | 12.91 Million EUR | -47.17% |
| 2021 Q1 | 12.22 Million EUR | -52.83% |
| 2021 Q4 | 25.81 Million EUR | 99.89% |
| 2020 Q1 | 10.36 Million EUR | -53.29% |
| 2020 Q2 | 20.73 Million EUR | 99.98% |
| 2020 FY | 46.13 Million EUR | 12.94% |
| 2020 Q3 | 13.03 Million EUR | -37.13% |
| 2020 Q4 | 25.91 Million EUR | 98.82% |
| 2019 Q2 | 18.65 Million EUR | 100.05% |
| 2019 Q4 | 22.19 Million EUR | 98.92% |
| 2019 Q1 | 9.32 Million EUR | -56.87% |
| 2019 FY | 40.84 Million EUR | 4.78% |
| 2019 Q3 | 11.15 Million EUR | -40.19% |
| 2018 Q2 | 17.36 Million EUR | 100.0% |
| 2018 FY | 38.98 Million EUR | 13.79% |
| 2018 Q4 | 21.61 Million EUR | 100.0% |
| 2018 Q3 | 10.8 Million EUR | -37.76% |
| 2018 Q1 | 8.68 Million EUR | -51.68% |
| 2017 Q1 | 8.14 Million EUR | -48.36% |
| 2017 Q3 | 8.98 Million EUR | -44.84% |
| 2017 Q4 | 17.97 Million EUR | 100.0% |
| 2017 Q2 | 16.29 Million EUR | 100.0% |
| 2017 FY | 34.26 Million EUR | 9.16% |
| 2016 Q4 | 15.77 Million EUR | 100.0% |
| 2016 FY | 31.38 Million EUR | 11.24% |
| 2016 Q2 | 15.61 Million EUR | 100.0% |
| 2016 Q3 | 7.88 Million EUR | -49.48% |
| 2016 Q1 | 7.8 Million EUR | -44.93% |
| 2015 Q1 | 7.02 Million EUR | -42.3% |
| 2015 Q3 | 7.08 Million EUR | -49.52% |
| 2015 Q2 | 14.04 Million EUR | 100.0% |
| 2015 FY | 28.21 Million EUR | 10.71% |
| 2015 Q4 | 14.17 Million EUR | 100.0% |
| 2014 Q4 | 12.16 Million EUR | 100.0% |
| 2014 Q1 | 6.65 Million EUR | -40.35% |
| 2014 FY | 25.48 Million EUR | 10.22% |
| 2014 Q2 | 13.31 Million EUR | 100.0% |
| 2014 Q3 | 6.08 Million EUR | -54.32% |
| 2013 Q3 | 5.58 Million EUR | -53.32% |
| 2013 Q1 | 5.97 Million EUR | 0.0% |
| 2013 FY | 23.12 Million EUR | 14.79% |
| 2013 Q2 | 11.95 Million EUR | 100.0% |
| 2013 Q4 | 11.16 Million EUR | 100.0% |
| 2012 FY | 20.14 Million EUR | 11.99% |
| 2011 FY | 17.98 Million EUR | 3.98% |
| 2010 FY | 17.29 Million EUR | 14.99% |
| 2009 FY | 15.04 Million EUR | 482.04% |
| 2008 FY | -3.93 Million EUR | 65.21% |
| 2007 FY | -11.31 Million EUR | -198.41% |
| 2006 FY | 11.5 Million EUR | 19.56% |
| 2005 FY | 9.61 Million EUR | 13.62% |
| 2004 FY | 8.46 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Cegedim SA | 19.98 Million EUR | -176.275% |
| Guerbet SA | 38.67 Million EUR | -42.763% |
| Nexus AG | 24.76 Million EUR | -122.919% |
| Bastide Le Confort Médical SA | 44.22 Million EUR | -24.843% |
| Revenio Group Oyj | 26.34 Million EUR | -109.574% |
| Drägerwerk AG & Co. KGaA | 171.18 Million EUR | 67.749% |
| Sartorius Aktiengesellschaft | 541 Million EUR | 89.795% |
| LNA Santé SA | 62.98 Million EUR | 12.342% |
| Siemens Healthineers AG | 2.86 Billion EUR | 98.076% |
| Medios AG | 31.37 Million EUR | -75.984% |
| Stratec SE | 22.88 Million EUR | -141.209% |